ADC Therapeutics SA (NYSE:ADCT) Q4 2023 Results Earnings Conference Call March 13, 2024 8:30 AM ET Company Participants Nicole Preiss-Riley - Executive Director, Head of Communications Ameet Mallik - Chief Executive Officer Kristen Herrington-Smith - Chief Commercial Officer Mohamed Zaki - Chief Medical Officer Patrick van Berkel - Chief Scientific Officer Jose Carmona - Chief Financial Officer Conference Call Participants Naureen Quibria - Capital One Securities, Inc. Brian Cheng - J.P. Morgan Gregory Renz ...

4Q 2023 Earnings Call Forward-Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or ADC Therapeutics or any officer, director, employee, agent or advisor of ADC Therapeutics. This presentation does not purport to be ...

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.30 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -119.15%. A quarter ago, it was expected that this company would post a loss of $0.61 per share when it actually produced a loss of $0.58, delivering a surprise of 4.92%.Over the last four quarters, the company has sur ...

ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $16.6 million in 4Q 2023 and $69.1 million for full year (FY) 2023; 4Q sales grew sequentially in both academic and community settings Focused pipeline progressing with continued LOTIS-7 dose escalation, screening patients for ADCT-601 targeting AXL in pancreatic cancer, and advancing differentiated solid tumor research platform FY 2023 operating expenses decreased 21%1 year-over-year due to portfolio prioritization and operational efficiencies; $278.6M o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Switzerland Not Applicable (State or other jurisdic ...

Company Overview - ADC Therapeutics is a commercial-stage global leader in antibody drug conjugates (ADCs) [2] - The company is focused on transforming treatment for patients with hematologic malignancies and solid tumors [2] - ADC Therapeutics is headquartered in Lausanne, Switzerland, with operations in London, the San Francisco Bay Area, and New Jersey [3] Product Development - ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy [2] - ZYNLONTA is also being developed in combination with other agents and in earlier lines of therapy [2] - The company has multiple ADCs in ongoing clinical and preclinical development [2] Upcoming Events - Ameet Mallik, CEO of ADC Therapeutics, will participate in a fireside chat at the Guggenheim 5th Annual Healthy Altitudes Summit on March 12, 2024 [1] - A live webcast of the presentation will be available on the company's Investors section of the website [1]

The market expects ADC Therapeutics SA (ADCT) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, ...

With patience, some of the most undervalued biotech stocks can create massive wealth.Look at ACADIA Pharmaceuticals (NASDAQ:ACAD), for example. At one point, it traded at 70 cents, as it developed treatment for Parkinson’s disease psychosis. Years later, it would hit a high of $45.10 for a win of about 6,300%. Most recently, and in far less time, CRISPR Therapeutics (NASDAQ:CRSP) exploded from a low of about $40 to a high of nearly $77.50. Even Corbus Pharmaceuticals (NASDAQ:CRBP) popped from about $5 to a ...

January’s payrolls report shows 353,000 jobs … wage growth accelerates … the biotech sector is on fire … will you play it for short- or long-term gains? … how Luke Lango and Eric Fry view itNo recession in sight.That’s the takeaway from this morning’s nonfarm payrolls report.It showed the U.S. economy added 353,000 jobs in January, destroying the Dow Jones estimate for 185,000.Similarly, the increase in average hourly earnings towered above estimates. It came in at 0.6% on the month, double what economists ...

ADC Therapeutics (ADCT) is a commercial-stage biotech company focused on developing novel antibody-drug conjugates (ADC) to treat patients with hematologic malignancies and solid tumors.Currently, ADC Therapeutics has only one marketed drug in its portfolio, Zynlonta, which the FDA approves to treat relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) in the third or later-line setting.Management is also evaluating Zynlonta in combination with other agents and earlier lines of therapy. Apart f ...